Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2016-03-03
2017-07-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* 10 patients with Broncho Chronic Obstructive Pulmonary Disease (COPD)
* 10 patients with asthma
* 10 patients with cystic fibrosis
* 10 healthy volunteers.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
During the first visit :
* Patients with COPD or cystic fibrosis will have a spontaneous expectoration
* Then all study participants will have an induced expectoration with hypertonic salin solution (4.5%).
During the second visit :
* Patients with COPD or cystic fibrosis will have a spontaneous expectoration
* Then, patients with COPD, asthma and healthy volunteers will have an induced expectoration with hypertonic salin solution (4.5%). Patients with cystic fibrosis will have a spontaneous expectoration 1 hour after an RhDNAse nebulization.
A control spirometry will be perform before each expectoration and during induced expectoration if necessary.
All sputum sample collected will be homogenized and then divided into two equal volumes in order to perform two separate rheological measurements of 15 minutes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rheological measurement of sputum
patients with COPD and patient with cystic fibrosis will perform a spontaneous expectoration.
Then all participants will have an induced expectoration with hypertonic salin solution.
Expectoration and measurement of sputum rheological properties
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Expectoration and measurement of sputum rheological properties
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No smoker
* No acute disease in the previous month
\- cystic fibrosis with bronchial disorder. Diagnosis confirmed by a reference center
\- COPD with FEV1/Forced Vital Capacity (FVC) \<70% after administration of a beta-2 agonist
\- diagnosis of asthma confirmed by a Pulmonologist
Exclusion Criteria
* contraindications for spirometry
* pregnant woman
* Forced Expiratory Volume in 1 second (FEV1 ) ≤ 40%, contraindications for RhDNAse, patient with chronic impairment of lung function (PaO2\<60 mmHg at rest). Patient who is unable to perform a spontaneous expectoration.
* case of acute exacerbation during the last month
* contraindications for spirometry
* pregnant woman
* Patient with chronic impairment of lung function and/or FEV1≤ 40%. Patient who is unable to perform a spontaneous expectoration.
* case of acute exacerbation during the last month
* contraindications for spirometry
* pregnant woman
* Patient with chronic impairment of lung function and/or FEV1≤ 50%.
* Very unstable Asthma
* case of acute exacerbation during the last month
* contraindications for spirometry
* pregnant woman
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'Investigation Clinique - INSERM 1406
Grenoble, Isere, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC14.444
Identifier Type: -
Identifier Source: org_study_id